Pyxis Oncology is trading 7% up today, benefiting from a broader biotech sector rally and renewed risk appetite despite a lack of fresh company-specific news.
- The upward move follows a stretch of high volatility and strong 30-day performance for the stock.
- Positive sentiment across the biotech space is being driven by recent merger activity and encouraging clinical trial data from industry peers.
- No new regulatory filings or corporate announcements have been released by the company to account for today's price action.